Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Alpha Cognition in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.72) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Alpha Cognition's Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.02) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.67) EPS.
Alpha Cognition Price Performance
NASDAQ ACOG traded down $0.04 on Thursday, reaching $5.33. 46,174 shares of the company were exchanged, compared to its average volume of 81,280. The firm has a fifty day simple moving average of $5.89. The company has a market cap of $85.39 million, a PE ratio of -2.08 and a beta of 2.50. Alpha Cognition has a fifty-two week low of $4.66 and a fifty-two week high of $7.00.
Institutional Investors Weigh In On Alpha Cognition
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Solas Capital Management LLC acquired a new stake in shares of Alpha Cognition during the fourth quarter worth about $8,096,000. Sphera Funds Management LTD. purchased a new position in shares of Alpha Cognition in the 4th quarter valued at about $3,652,000. Alyeska Investment Group L.P. acquired a new position in Alpha Cognition during the 4th quarter worth approximately $2,356,000. Altium Capital Management LLC acquired a new position in shares of Alpha Cognition during the fourth quarter worth $1,620,000. Finally, Rosalind Advisors Inc. acquired a new position in shares of Alpha Cognition during the fourth quarter worth $1,489,000.
Alpha Cognition Company Profile
(
Get Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Read More
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
